Thank you! Your submission has been received!
It looks like that email is already in our system - thanks for signing up!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
back to portfolio︁
Excision BioTherapeutics

Excision develops CRISPR-based therapies to cure viral infectious diseases. The company’s first targeted viral infection is HIV, with a pipeline to begin trials on treatments for Herpes Simplex Virus, JC Virus/PML andHepatitis B in the next ~2-3 years.

The Excision approach is the first technology in history to remove HIV genomes from animals and generate a functional cure for HIV.



Daniel Dornbusch


Michael Marks


Life Sciences


San Francisco, Calif.

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.